Scarica l'app Stockscreener
10.97
5.94%
0.615
Dopo l'orario di chiusura:
10.96
-0.010
-0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera Director Michael R. Hayden Donates 50,000 Shares to Charity via Genworks 2 Consulting - Kalkine Media
AbCellera Biologics Announces Oversubscribed $200 Million Offering - TipRanks
AbCellera Enters Underwriting Agreement for $187M Equity Offering With Jefferies, J.P. Morgan - TradingView
AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - AOL.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Abcellera Biologics Inc Nasdaq ABCL Canada F-35 Fighter Jet Purchase (hA9yM7fsuE) - Mshale
ABCL Looks 82.6% Overvalued on GF Value™ - GuruFocus
AbCellera prices $200 million public offering at $9.75/share - Investing.com
AbCellera prices $200 million public offering at $9.75/share By Investing.com - Investing.com Nigeria
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - lincolnjournal.com
AbCellera (ABCL) Q2 2026 Earnings Call Transcript - AOL.com
AbCellera Biologics stock analysis: momentum vs. fundamentals By Investing.com - Investing.com Canada
AbCellera Biologics stock analysis: momentum vs. fundamentals - Investing.com
What's Going on With AbCellera Biologics Stock On Wednesday? - Benzinga
AbCellera Biologics (NASDAQ:ABCL) Shares Gap DownHere's Why - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL) - Moomoo
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stoc - Benzinga
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
AbCellera offers up USD 200m in stock to support NK3 menopause antibody - AllSci
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Ifc (po852VQ6WV) - Mshale
AbCellera’s ABCL635 Meets Primary Endpoints in Phase 2 for Menopause Symptoms - The Clinical Trial Vanguard
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal - Yahoo Finance
AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story - simplywall.st
AbCellera Biologics | 424B5: Prospectus - Moomoo
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031 - Bybit
Truist raises AbCellera stock price target on trial results By Investing.com - Investing.com South Africa
AbCellera launches $200-million equity offering on heels of strong menopause trial results - The Globe and Mail
AbCellera launches $200 million public offering of common shares By Investing.com - Investing.com UK
ABCL Looks 72.1% Overvalued on GF Value™ - GuruFocus
Why is Abcellera Biologics stock sliding today? - Investing.com
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results - Yahoo Finance
AbCellera stock falls on $200M public offering launch By Investing.com - Investing.com India
AbCellera stock falls on $200M public offering launch - Investing.com
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading - Seeking Alpha
AbCellera launches $200 million public offering of common shares - Investing.com
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
ABCL Maintained by Truist Securities -- Price Target Raised to $30 - GuruFocus
AbCellera Shares Jump on Trial Results Amid Interest in Menopause Drugs - Moomoo
Truist Financial Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.7%Here's What Happened - MarketBeat
Truist raises AbCellera stock price target on trial results - Investing.com
This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News. -- Barrons.com - moomoo.com
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data - Yahoo! Finance Canada
AbCellera stock surges on ABCL635 menopause Phase 2 trial results - qz.com
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes - BioSpace
Is AbCellera Biologics (ABCL) Fully Valued After Its 172% Run? - Yahoo Finance
AbCellera Soars Nearly 40% as Menopause Drug Data ‘Wows’ Analysts - NAI500
ABCL635, a drug for hot flash treatment, shows positive results in mid-stage trials; AbCellera Biologics (ABCL.US) surges in response - Bitget
Positive results from the mid-stage trial of the hot flash treatment drug ABCL635, AbCellera Biologics (ABCL.US) surges in response - Bitget
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook - Yahoo Finance
AbCellera stock soars 35% on successful clinical trial result - Business in Vancouver
AbCellera Biologics | 8-K: Current report - Moomoo
AbCellera Jumps 32% After Menopause Drug Slashes Hot Flashes in Phase 2 Trial - finance.biggo.com
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News. - Barron's
Hot-Flash Drug Trial Result Sends AbCellera Up as Much as 41% - Bloomberg.com
ABCL Looks 64.1% Overvalued on GF Value™ Amid Promising Clinical News - GuruFocus
AbCellera Biologics Sees Unusually High Options Volume (NASDAQ:ABCL) - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi - StreetInsider
AbCellera Biologics (NASDAQ:ABCL) Reaches New 12-Month HighStill a Buy? - MarketBeat
Abcellera Biologics stock hits 52-week high at 8.79 USD By Investing.com - Investing.com South Africa
Abcellera Biologics stock hits 52-week high at 8.79 USD - Investing.com
Why is Abcellera Biologics stock surging today? - Investing.com
0.03%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):